NCT05446506

Serum Levels of Otolin-1 and Vitamin D in Pre- and Post-treatments of BPPV

Completed Last updated 31 August 2023

What this trial tests

trial in Benign Paroxysmal Positional Vertigo in 21 participants. Completed in 28 February 2023.

Timeline

13 January 2021

Primary endpoint
30 September 2022

28 February 2023

Quick facts

Lead sponsor	Chiang Mai University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	21
Start date	13 January 2021
Primary completion	30 September 2022
Estimated completion	28 February 2023
Sites	1 location across Thailand

Conditions studied

• Benign Paroxysmal Positional Vertigo — all drugs for Benign Paroxysmal Positional Vertigo →

Sponsor

Chiang Mai University

Who can join

Adults 18 to 80, any sex, with Benign Paroxysmal Positional Vertigo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BPPV is the most common cause of vertigo. The pathophysiology of BPPV has not been cleared, several studies show that symptoms are caused by the displacement of otoconia from the macula of the utricle into the semicircular canals. These calcium carbonate particles then stimulate non-physiological movement of the endolymph leading to a false sensation of angular acceleration.

Biomarkers represent measurable products of biological processes, thus making an assessment of those processes more practical. Biomarkers in circulation are powerful indicators of normal and pathological biological processes, as well as, responses to pharmacological treatments. The inner ear-inclusive protein that has been published included Otolin-1, Otoconin-90/95, Prestin, Otoancorin, Otogelin, α-tectorin, β-tectorin and Cochlin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.